Menu
GeneBe

rs104894425

Variant summary

Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PM2PP3_StrongPP5_Very_Strong

The NM_014239.4(EIF2B2):c.638A>G(p.Glu213Gly) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000657 in 1,613,598 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Synonymous variant affecting the same amino acid position (i.e. E213E) has been classified as Likely benign.

Frequency

Genomes: 𝑓 0.000072 ( 0 hom., cov: 33)
Exomes 𝑓: 0.000065 ( 0 hom. )

Consequence

EIF2B2
NM_014239.4 missense

Scores

11
6
2

Clinical Significance

Pathogenic criteria provided, multiple submitters, no conflicts P:11O:2

Conservation

PhyloP100: 8.97
Variant links:
Genes affected
EIF2B2 (HGNC:3258): (eukaryotic translation initiation factor 2B subunit beta) This gene encodes the beta subunit of eukaryotic initiation factor-2B (EIF2B). EIF2B is involved in protein synthesis and exchanges GDP and GTP for its activation and deactivation. [provided by RefSeq, Aug 2011]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Pathogenic. Variant got 14 ACMG points.

PM2
Very rare variant in population databases, with high coverage;
PP3
MetaRNN computational evidence supports a deleterious effect, 0.95
PP5
Variant 14-75005906-A-G is Pathogenic according to our data. Variant chr14-75005906-A-G is described in ClinVar as [Pathogenic]. Clinvar id is 4336.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr14-75005906-A-G is described in Lovd as [Pathogenic].

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE UniProt
EIF2B2NM_014239.4 linkuse as main transcriptc.638A>G p.Glu213Gly missense_variant 5/8 ENST00000266126.10

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Appris UniProt
EIF2B2ENST00000266126.10 linkuse as main transcriptc.638A>G p.Glu213Gly missense_variant 5/81 NM_014239.4 P1
ENST00000554430.1 linkuse as main transcriptn.287-985T>C intron_variant, non_coding_transcript_variant 3

Frequencies

GnomAD3 genomes
AF:
0.0000722
AC:
11
AN:
152252
Hom.:
0
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.0000241
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.000147
Gnomad OTH
AF:
0.00
GnomAD3 exomes
AF:
0.0000318
AC:
8
AN:
251480
Hom.:
0
AF XY:
0.0000441
AC XY:
6
AN XY:
135910
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.0000703
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.0000650
AC:
95
AN:
1461346
Hom.:
0
Cov.:
31
AF XY:
0.0000619
AC XY:
45
AN XY:
726990
show subpopulations
Gnomad4 AFR exome
AF:
0.00
Gnomad4 AMR exome
AF:
0.00
Gnomad4 ASJ exome
AF:
0.00
Gnomad4 EAS exome
AF:
0.00
Gnomad4 SAS exome
AF:
0.00
Gnomad4 FIN exome
AF:
0.00
Gnomad4 NFE exome
AF:
0.0000855
Gnomad4 OTH exome
AF:
0.00
GnomAD4 genome
AF:
0.0000722
AC:
11
AN:
152252
Hom.:
0
Cov.:
33
AF XY:
0.0000807
AC XY:
6
AN XY:
74386
show subpopulations
Gnomad4 AFR
AF:
0.0000241
Gnomad4 AMR
AF:
0.00
Gnomad4 ASJ
AF:
0.00
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.00
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.000147
Gnomad4 OTH
AF:
0.00
Alfa
AF:
0.000139
Hom.:
0
Bravo
AF:
0.0000718
ExAC
AF:
0.0000330
AC:
4
EpiCase
AF:
0.000218
EpiControl
AF:
0.00

ClinVar

Significance: Pathogenic
Submissions summary: Pathogenic:11Other:2
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Vanishing white matter disease Pathogenic:4Other:2
Pathogenic, criteria provided, single submitterclinical testingIllumina Laboratory Services, IlluminaSep 21, 2018The EIF2B2 c.638A>G (p.Glu213Gly) variant has been reported in three studies in which it is found in a total of 24 individuals with childhood ataxia with central nervous system hypomyelination/vanishing white matter including 15 homozygotes (including 11 siblings from five families) and nine compound heterozygotes (Leegwater et al. 2001; Fogli et al. 2004; Ohlenbusch et al. 2005). The p.Glu213Gly variant was absent from 307 controls (Leegwater et al. 2001, Fogli et al. 2004, Ohlenbusch et al. 2005) and is reported at a frequency of 0.000087 in the European (non-Finnish) population of the Genome Aggregation Database. Li et al. (2004) demonstrated in transfected HEK 293 cells that the p.Glu213Gly variant does not affect assembly of the EIF2B translation initiation factor complex but it does decrease EIF2B2 enzyme activity to 40-60% of wild type. In vivo assays also showed that the p.Glu213Gly variant enhanced eIF2 binding (Li et al. 2004). Based on the collective evidence, the p.Glu213Gly variant is classified as pathogenic for childhood ataxia with central nervous system hypomyelination/vanishing white matter. -
not provided, no classification providedphenotyping onlyGenomeConnect, ClinGen-Variant interpretted as pathogenic and reported on 03/14/2018 by GTR ID 26957. GenomeConnect assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. GenomeConnect staff make no attempt to reinterpret the clinical significance of the variant. -
not provided, no classification providedliterature onlyGeneReviews-Dutch founder variant, associated w/relatively mild disease -
Pathogenic, criteria provided, single submitterclinical testingVictorian Clinical Genetics Services, Murdoch Childrens Research InstituteMay 06, 2021Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Pathogenic. Following criteria are met: 0102 - Loss of function is a known mechanism of disease in this gene and is associated with leukoencephalopathy with vanishing white matter (MIM#603896). (I) 0106 - This gene is associated with autosomal recessive disease. (I) 0200 - Variant is predicted to result in a missense amino acid change from glutamic acid to glycine. (I) 0251 - This variant is heterozygous. (I) 0304 - Variant is present in gnomAD <0.01 for a recessive condition (v3: 11 heterozygotes, 0 homozygotes). (SP) 0501 - Missense variant consistently predicted to be damaging by multiple in silico tools or highly conserved with a major amino acid change. (SP) 0600 - Variant is located in the annotated IF-2B domain (NCBI, DECIPHER). (I) 0801 - This variant has strong previous evidence of pathogenicity in unrelated individuals. It has been found in at least ten individuals with vanishing white matter and classified as pathogenic by diagnostic laboratories in Clinvar (PMID: 15136673, 31438897). (SP) 1205 - This variant has been shown to be maternally inherited (by trio analysis). (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign -
Pathogenic, criteria provided, single submitterclinical testingWomen's Health and Genetics/Laboratory Corporation of America, LabCorpNov 05, 2021Variant summary: EIF2B2 c.638A>G (p.Glu213Gly) results in a non-conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 3.2e-05 in 251480 control chromosomes. c.638A>G has been reported in the literature as homozygous and compound heterozygous genotypes in multiple individuals affected with Leukoencephalopathy With Vanishing White Matter (examples- Leegwater_2001, Fogli_2004). These data indicate that the variant is very likely to be associated with disease. Several publications report experimental evidence that homozygous cell lines with the variant demonstate reduced EIF2B2 guanine nucleotide exchange factor activity (examples- Li_2004, Fogli_2004). One clinical diagnostic laboratory and the Gene Reviews database have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. Both submitters cited the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. -
Pathogenic, criteria provided, single submitterclinical testingCenter for Genomics, Ann and Robert H. Lurie Children's Hospital of ChicagoMar 30, 2021EIF2B2 NM_014239.3 exon 5 p.Glu213Gly (c.638A>G): This variant has been reported in the literature in multiple individuals with features of leukodystrophy/vanishing white matter (at least 10 individuals in the homozygous state, 6 individuals in the compound heterozygous state), segregating with disease in at least 3 affected family members (Leegwater 2001 PMID:11704758, Fogli 2004 PMID:15136673, Ohlenbusch 2005 PMID:15776425). This variant is present in 10/129186 European alleles in the Genome Aggregation Database (https://gnomad.broadinstitute.org/variant/14-75472609-A-G). Please note, disease causing variants may be present in control databases at low frequencies, reflective of the general population, carrier status and/or variable expressivity. This variant is present in ClinVar (Variation ID:4336). Evolutionary conservation and computational predictive tools suggest that this variant may impact the protein. In addition, functional studies support that this variant will impact the protein (Li 2004 PMID:15060152, Liu 2011 PMID:21560189). In summary, this variant is classified as pathogenic. -
not provided Pathogenic:3
Pathogenic, criteria provided, single submitterclinical testingInvitaeJan 24, 2024This sequence change replaces glutamic acid, which is acidic and polar, with glycine, which is neutral and non-polar, at codon 213 of the EIF2B2 protein (p.Glu213Gly). This variant is present in population databases (rs104894425, gnomAD 0.009%). This missense change has been observed in individuals with leukoencephalopathy with vanishing white matter (PMID: 11704758, 12707859, 15136673, 21560189). ClinVar contains an entry for this variant (Variation ID: 4336). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt EIF2B2 protein function with a negative predictive value of 80%. Experimental studies have shown that this missense change affects EIF2B2 function (PMID: 15060152). For these reasons, this variant has been classified as Pathogenic. -
Pathogenic, criteria provided, single submitterclinical testingGeneDxMar 04, 2022In vitro studies have shown that in the homozygous state E213G enzyme activity was reduced by approximately 50%, and when reported with a second EIF2B2 variant (phase unknown) reduced translation was observed (Liu et al., 2011; Moon et al., 2018); Not observed at a significant frequency in large population cohorts (gnomAD); In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect; This variant is associated with the following publications: (PMID: 31438897, 33432707, 21560189, 22729508, 20958979, 18263758, 12707859, 16823698, 11704758, 15776425, 29632131, 31589614) -
Pathogenic, criteria provided, single submitterclinical testingAiLife Diagnostics, AiLife DiagnosticsJun 10, 2021- -
Leukoencephalopathy with vanishing white matter 2 Pathogenic:2
Pathogenic, no assertion criteria providedliterature onlyOMIMJun 01, 2003- -
Pathogenic, criteria provided, single submitterclinical testingRevvity Omics, RevvityAug 18, 2021- -
See cases Pathogenic:1
Pathogenic, criteria provided, single submitterclinical testingLaboratorio de Genetica e Diagnostico Molecular, Hospital Israelita Albert EinsteinSep 01, 2021ACMG classification criteria: PS3, PM3, PP3 -
EIF2B2-related disorder Pathogenic:1
Pathogenic, criteria provided, single submitterclinical testingPreventionGenetics, part of Exact SciencesJan 10, 2024The EIF2B2 c.638A>G variant is predicted to result in the amino acid substitution p.Glu213Gly. This variant was reported in the homozygous or compound heterozygous states in individuals with leukoencephalopathy with vanishing white matter (see, for example, Leegwater et al. 2001. PubMed ID: 11704758; Liu et al. 2011. PubMed ID: 21560189; Sambati et al. 2012. PubMed ID: 22729508; Fogli et al. 2004. PubMed ID: 15054402). This variant is reported in 0.0077% of alleles in individuals of European (Non-Finnish) descent in gnomAD. This variant is interpreted as pathogenic. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Uncertain
0.44
BayesDel_addAF
Pathogenic
0.41
D
BayesDel_noAF
Pathogenic
0.54
Cadd
Pathogenic
32
Dann
Uncertain
1.0
DEOGEN2
Pathogenic
0.82
D;.
Eigen
Pathogenic
0.83
Eigen_PC
Pathogenic
0.82
FATHMM_MKL
Pathogenic
0.99
D
LIST_S2
Benign
0.80
T;D
M_CAP
Pathogenic
0.41
D
MetaRNN
Pathogenic
0.91
D;D
MetaSVM
Pathogenic
1.0
D
MutationAssessor
Uncertain
2.8
M;.
MutationTaster
Benign
1.0
A
PrimateAI
Uncertain
0.70
T
PROVEAN
Pathogenic
-5.0
D;D
REVEL
Pathogenic
0.97
Sift
Uncertain
0.017
D;D
Sift4G
Uncertain
0.028
D;D
Polyphen
0.95
P;.
Vest4
0.95
MVP
1.0
MPC
1.3
ClinPred
0.89
D
GERP RS
5.5
Varity_R
0.93
gMVP
0.75

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.050
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs104894425; hg19: chr14-75472609; API